44 results about "Variable domain" patented technology

Disclosed herein is an anti-transferrin receptor antibody that specifically binds to the human transferrin receptor and the rhesus monkey transferrin receptor, comprising i) a humanized heavy chain variable domain derived from the heavy chain variable domain of SEQ ID NO:01, and ii) a humanized light chain variable domain derived from the light chain variable domain of SEQ ID NO:26, wherein the dissociation rate of the antibody for the human transferrin receptor is equal to or less than (i.e., at most) the dissociation rate of anti-transferrin receptor antibody 128.1 for the rhesus monkey transferrin receptor, wherein the dissociation rate is determined by surface plasmon resonance, and anti-transferrin receptor antibody 128.1 has a heavy chain variable domain of SEQ ID NO:64 and a light chain variable domain of SEQ ID NO:65.

Herein is reported an antibody that binds to human A-beta protein, wherein the antibody comprises a heavy chain variable domain (VH) and a light chain variable domain comprising CDRs selected from (1) CDRs of SEQ ID NO: 85, 86, 87, 81, 82 and 83; or (2) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 83; or (3) CDRs of SEQ ID NO: 85, 86, 87, 81, 82 and 91; or (4) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 91.

Herein is reported an antibody that binds to human A-beta protein, wherein the antibody comprises a heavy chain variable domain (VH) and a light chain variable domain comprising CDRs selected from (1) CDRs of SEQ ID NO: 85, 86, 87, 81, 82 and 83; or (2) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 83; or (3) CDRs of SEQ 5 ID NO: 85, 86, 87, 81, 82 and 91; or (4) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 91.

The present invention relates to the identification of antibodies and / or antibody fragments in a selection process. The present invention relates to a method, a system and a computer program product for identifying pairs of genes which encode the variable domains of light and heavy chains of selected antibodies and / or antibody fragments.

The disclosure provides a polypeptide comprising an antibody heavy chain variable domain (VH) variant comprising a plurality of antigen-binding regions and a framework comprising framework region 1, framework region 2 and framework region 3 (FWR3), wherein the VH variant has an amino acid sequence in which at least eight of the following criteria i) to x) are fulfilled: i) the residue in Kabat position 19 is R, S, K or T; ii) the residue in Kabat position 23 is T, V, A or S; iii) the residue in Kabat position 24 is I, V or S; iv) the residue in Kabat position 40 is selected from R, I, T or K; v) the residue in Kabat position 43 is R, K, Q, E or G; vi) the residue in Kabat position 44 is E, Q, A, D or G; vii) the residue in Kabat position 45 is R, I or L; viii) the residue in Kabat position 76 is N or Q; ix) the residue in Kabat position 79 is Y, A, W or F; and x) the residue in Kabat position 89 is V, I, L or A. The VH variants have improved alkaline stability and are useful as a scaffold for an affinity binder for in vitro applications, such as detection, analysis or separation of an analyte based on affinity interactions.

Aspects of the disclosure relate to PD-1 binding proteins comprising immunoglobulin domains which bind specifically to PD-1 and comprise at least three or six specific complementarity determining regions (CDRs) and which comprise a specific feature in a variable domain framework region(s), e.g., heavy variable domain framework 1, heavy domain framework 4, and / or light chain variable domain framework 3 region(s). In some embodiments, the PD-1 protein comprises the substitution(s) L 108G and / or THOR of the heavy chain reference sequence and / or 158R relative to the light chain reference sequence(s). The PD-1 binding proteins are useful, e.g., as immunologic adjuvants, for detecting and quantifying PD-1, monitoring patient responses to therapies, diagnosing PD-1 related conditions, and treating or preventing disorders involving PD-1 expressing cells, such as, e.g., cancers and autoimmune diseases. Also provided herein are antigen binding proteins comprising amino acid substitutions in the heavy chain framework 4 region for improved stability and solubility.

Provided herein are methods and compositions for disrupting bio films in vitro and in vivo. Also disclosed are antibodies comprising a specified heavy chain (HC) immunoglobulin variable domain sequence and / or a specified light chain (LC) immunoglobulin variable domain sequence.

The invention as disclosed herein relates to bispecific antibodies that comprises a first variable domain that can bind an extracellular part of epidermal growth factor receptor (EGFR) and a second variable domain that can bind an extracellular part of MET Proto-Oncogene, Receptor Tyrosine Kinase (cMET). The antibody may comprise a common light chain. It may be a human antibody. The antibody may be a full length antibody. In some embodiments the bispecific antibody is an IgG1 format antibody having an anti-EGFR, anti-cMET stoichiometry of 1:1. In some embodiment the antibody has one variable domain that can bind EGFR and one variable domain that can bind cMET.

The present disclosure provides dual variable domain immunoglobulin (DVD-Ig) molecules that bind to human STEAP1 and human PSMA and their drug conjugates, and methods of using the same.

The present disclosure provides dual variable domain immunoglobulin (DVD-Ig) molecules that bind to human STEAP1 and human PSMA and their drug conjugates, and methods of using the same.

Herein is reported an anti-TREM2 antibody specifically binding to human TREM2 comprising in the heavy chain variable domain a HVR-H1 of SEQ ID NO: 305, a HVR-H2 of SEQ ID NO: 306 and a HVR-H3 of SEQ ID NO: 307, and in the light chain variable domain a HVR-L1 of SEQ ID NO: 309, a HVR-L2 of SEQ ID NO: 310 and a HVR-L3 of SEQ ID NO: 311 (TREM2 3295), or in the heavy chain variable domain a HVR-H1 of SEQ ID NO: 329, a HVR-H2 of SEQ ID NO: 330 and a HVR-H3 of SEQ ID NO: 331, and in the light chain variable domain a HVR-L1 of SEQ ID NO: 333, a HVR-L2 of SEQ ID NO: 334 and a HVR-L3 of SEQ ID NO: 335 (TREM2 3306), wherein the does not induce pSyk in the absence or presence of human Abeta protein.

To provide humanized versions of the murine anti-IL17BR antibody D9.2 comprising mutations of certain residues within the heavy and / or light chain variable domains, which exhibit improved expression without adversely affecting specificity or affinity.SOLUTION: Provided is an antibody comprising a heavy chain variable domain and a light chain variable domain, wherein: a) the heavy chain variable domain comprises a VHCDR1, VHCDR2, and VHCDR3 each having a specific sequence, and b) the light chain variable domain (VK domain) comprises a VLCDR1, VLCDR2, and VLCDR3 each having a specific sequence.SELECTED DRAWING: Figure 1

The present invention relates to heavy chain only variable domain (VHH) antibodies that specifically bind to transferrin receptor 1 (TfR1) and their use for transporting therapeutic or imaging agents into cells and across the blood brain barrier.

This disclosure relates to an immunoglobulin molecule having multiple variable domains that are each specific for a receptor, as well as heterodimeric molecules that include the multivariable domain immunoglobulin and a second heavy chain constant domain (HCCD2) of an antibody comprising a CH1 and a second Fc region (FC2), where FC1 and FC2 heterodimerize.

The disclosure provides a polypeptide comprising an antibody heavy chain variable domain (VH) variant comprising a plurality of antigen-binding regions and a framework comprising framework region 1, framework region 2 and framework region 3 (FWR3), wherein the VH variant has an amino acid sequence in which at least eight of the following criteria i) to x) are fulfilled: i) the residue in Kabat position 19 is R, S, K or T; ii) the residue in Kabat position 23 is T, V, A or S; iii) the residue in Kabat position 24 is I, V or S; iv) the residue in Kabat position 40 is selected from R, I, T or K; v) the residue in Kabat position 43 is R, K, Q, E or G; vi) the residue in Kabat position 44 is E, Q, A, D or G; vii) the residue in Kabat position 45 is R, I or L; viii) the residue in Kabat position 76 is N or Q; ix) the residue in Kabat position 79 is Y, W or F; and x) the residue in Kabat position 89 is V, or I. The VH variants have improved alkaline stability and are useful as a scaffold for an affinity binder for in vitro applications, such as detection, analysis or separation of an analyte based on affinity interactions.

Provided herein are methods and compositions for disrupting biofilms in vitro and in vivo. Also disclosed herein are antibodies comprising specific heavy chain (HC) immunoglobulin variable domain sequences and / or specific light chain (LC) immunoglobulin variable domain sequences.

Antibodies specific for Notch4 and related methods for treating conditions such as airway inflammation. Also provided are isolated nucleic acids encoding the heavy chain variable domain and / or light chain variable domain of the antibody or its antigen-binding fragment disclosed herein, as well as expression vectors comprising such isolated nucleic acids, and host cells comprising such isolated nucleic acids or expression vectors. Also provided are compositions comprising the Notch4 antibody or its Notch-binding fragment disclosed herein and a pharmaceutically acceptable carrier.

A single-domain antibody or an antigen-binding fragment thereof to Senecavirus A, the single-domain antibody or the antigen-binding fragment thereof being selected from 52 amino acid sequence groups, and each of the 52 amino acid sequence groups including a first variable domain of heavy chain VH-CDR-1, a second variable domain of heavy chain VH-CDR-2, and a third variable domain of heavy chain VH-CDR-3. The first variable domain of heavy chain VH-CDR-1 has an amino acid sequence represented by one of SEQ ID NO: 1-SEQ ID NO: 52. The second variable domain of heavy chain VH-CDR-2 has an amino acid sequence represented by one of SEQ ID NO: 53-SEQ ID NO: 104. The third variable domain of heavy chain VH-CDR-3 has an amino acid sequence represented by one of SEQ ID NO: 105-SEQ ID NO: 156.

Herein is reported an antibody that binds to human A-beta protein wherein the antibody comprises a heavy chain variable domain (VH) and a light chain variable domain, the heavy chain variable domain and the light chain variable domain comprising a CDR selected from the group consisting of: (1) a CDR of SEQ ID NO: 85, 86, 87, 81, 82 and 83; or (2) a CDR of SEQ ID NO: 85, 89, 87, 81, 82, and 83; or (3) a CDR of SEQ ID NO: 85, 86, 87, 81, 82 and 91; or (4) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 91.

To provide bispecific antibodies that comprise a first variable domain that can bind an extracellular part of epidermal growth factor receptor (EGFR), and a second variable domain that can bind an extracellular part of MET Proto-Oncogene, Receptor Tyrosine Kinase (cMET).SOLUTION: An antibody may comprise a common light chain, and may be a human antibody. The antibody may be a full-length antibody. In some embodiments, the bispecific antibody is an IgG1 format antibody having an anti-EGFR, anti-cMET stoichiometry of 1:1. In some embodiments, the antibody has one variable domain that can bind EGFR and one variable domain that can bind cMET.SELECTED DRAWING: None

The present disclosure provides dual variable domain immunoglobulin (DVD-Ig) molecules that bind to human STEAP1 and human PSMA and their drug conjugates, and methods of using the same.

The present invention relates to Camelidae heavy chain only variable domain (VHH) molecules that bind to TfR, coupling compounds comprising such VHH molecules and their use for transporting molecules of pharmaceutical interest to cells and organs, for example under pathological conditions of CNS or PNS, including cancer.

The present invention relates to heavy chain-only variable domain (VHH) antibodies that specifically bind to transferrin receptor 1 (TfR1) and their use for transporting therapeutic or imaging agents intracellularly and across the blood-brain barrier.

The invention as disclosed herein relates to bispecific antibodies that comprises a first variable domain that can bind an extracellular part of epidermal growth factor receptor (EGFR) and a second variable domain that can bind an extracellular part of MET Proto-Oncogene, Receptor Tyrosine Kinase (cMET). The antibody may comprise a common light chain. It may be a human antibody. The antibody may be a full length antibody. In some embodiments the bispecific antibody is an IgG1 format antibody having an anti-EGFR, anti-cMET stoichiometry of 1:1. In some embodiment the antibody has one variable domain that can bind EGFR and one variable domain that can bind cMET.

Antibodies comprising unpaired variable domains, e.g., heavy chain variable (VH) domains, for binding antigen. Antibody comprising two immunoglobulin (Ig) chains, wherein a first Ig chain comprises a variable domain and a constant domain, and a second Ig chain comprises a constant domain, wherein the second Ig chain lacks a variable domain, leaving the variable domain of the first Ig chain unpaired. The antibody may comprise two Ig heavy chains and two Ig light chains, each heavy chain comprising a VH domain and a constant region comprising a CH1 domain, and each light chain comprising a CL domain, wherein one or both light chains lack a VL domain, thereby leaving one or both VH domains unpaired. Non-human animals (e.g., mice) engineered to produce antibodies having unpaired VH domains, involving deletion of sequence coding for light chain variable (VL) domains. Use of unpaired VH domains to generate antigen-binding molecules.

The present invention relates to bispecific antibodies comprising a first variable domain that can bind to an extracellular portion of the epidermal growth factor receptor (EGFR) and a second variable domain that can bind to an extracellular portion of the MET proto-oncogene, tyrosine kinase receptor (cMET). The antibody may comprise a common light chain. It may be a human antibody. The antibody may be a full-length antibody. In some embodiments, the bispecific antibody is an IgG1-format antibody having a 1:1 anti-cMET, anti-EGFR stoichiometry. In some embodiments, the antibody has a variable domain that can bind to EGFR and a variable domain that can bind to cMET.

This disclosure provides a dual variable domain immunoglobulin (DVD-Ig) molecule that binds to human STEAP1 and human PSMA, drug conjugates thereof, and methods of using them.

This disclosure provides polypeptides comprising antibody heavy chain variable domain (VH) variants, the VH variants comprising multiple antigen-binding regions and a framework comprising framework region 1, framework region 2, and framework region 3 (FWR3), wherein the VH variants have an amino acid sequence satisfying at least eight of the following criteria i)-x): i) the residue at Kabat position 19 is R, S, K, or T; ii) the residue at Kabat position 23 is T, V, A, or S; iii) the residue at Kabat position 24 is I, V, or S; iv) the residue at Kabat position 40 is selected from R, I, T, or K; v) the residue at Kabat position 43 is R, K, Q, E, or G; vi) the residue at Kabat position 44 is E, Q, A, D, or G; vii) the residue at Kabat position 45 is R, I, or L; viiii) the residue at Kabat position 76 is N or Q; ix) the residue at Kabat position 79 is Y, W, or F; and x) the residue at Kabat position 89 is V or I. The VH variant has improved basic stability and can be used as a backbone for affinity binding agents for in vitro applications, such as detecting, analyzing or separating analytes based on affinity interactions.

The present invention provides VHH antibodies in which the pro-inflammatory interleukin, IL-17, is neutralized in the form of a homodimer of IL-17A and IL-17F, and a heterodimer of IL-17AF. Pharmaceutical compositions comprising the VHH antibodies and uses for the treatment of inflammatory and immune related diseases and disorders are also provided.